The European Commission (EC) has approved Roche’s recycling monoclonal antibody, PiaSky (crovalimab), for the treatment of ...

Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcutaneous ...

(RTTNews) - Roche (RHHBY) announced that the European Commission has approved PiaSky (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5. It is approved for ...

Roche Holding said that the European Commission has approved blood disorder injection PiaSky. The Swiss pharmaceutical giant said Tuesday that the approval follows a Phase III study which showed ...

PiaSky is a novel recycling monoclonal antibody that inhibits the complement protein C5. Per Roche, the drug is the first monthly subcutaneous (SC) treatment for people with PNH. The EC approved ...

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregivers ...

The European Commission (EC) has approved Roche’s recycling monoclonal antibody, PiaSky (crovalimab), for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adult and adolescent ...

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregivers Approval ...

Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the ...